ZymoGenetics, Inc.


Oct 25, 07

NEW STORY
06:00 ET ZymoGenetics to Host Conference Call and Webcast on October 31, 2007 to Discuss Third Quarter Results

 
Oct 23, 07

13:30 ET ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)

 
Oct 04, 07

06:00 ET ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis

 
Sep 06, 07

06:00 ET ZymoGenetics to Webcast Presentation at Two Upcoming Conferences

 
Aug 22, 07

16:05 ET ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin

 
Aug 01, 07

06:00 ET ZymoGenetics Reports Second Quarter 2007 Financial Results

 
Jul 25, 07

06:00 ET ZymoGenetics to Host Conference Call and Webcast on August 1, 2007 to Discuss Q2 2007 Financial Results

 
Jul 02, 07

06:00 ET ZymoGenetics Announces Senior Management Promotions

 
Jun 19, 07

07:30 ET ZymoGenetics Will Hold Conference Call on June 19 at 8:30 a.m. Eastern Time to Discuss rThrombin Collaboration with Bayer HealthCare

 
02:01 ET ZymoGenetics Establishes Global Collaboration With Bayer HealthCare for Development and Commercialization of Recombinant Human Thrombin

 
Jun 04, 07

06:00 ET ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

 
May 29, 07

06:00 ET ZymoGenetics Announces Upcoming Presentations at ASCO

 
May 17, 07

06:00 ET ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences

 
May 02, 07

16:05 ET ZymoGenetics Reports First Quarter 2007 Financial Results

 
Apr 26, 07

06:00 ET ZymoGenetics to Host Conference Call and Webcast on May 2, 2007 to Discuss Q1 2007 Financial Results

 
Apr 25, 07

06:00 ET ZymoGenetics to Webcast Presentation at Morgan Stanley Healthcare Conference

 
Mar 12, 07

06:00 ET ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences

 
Mar 07, 07

06:00 ET ZymoGenetics Provides Update on rhThrombin Development Plans

 
Feb 26, 07

12:16 ET ZymoGenetics to Webcast Presentation at RBC Dain Rauscher Northwest Investor Conference

 
Feb 15, 07

16:05 ET FDA Accepts ZymoGenetics' Recombinant Human Thrombin Application for Review

 
16:01 ET ZymoGenetics Reports Fourth Quarter and Year End 2006 Financial Results

 
Feb 07, 07

06:00 ET ZymoGenetics to Host Conference Call and Webcast on February 15, 2007 to Discuss 2006 Year-end Financial Results

 
Feb 01, 07

06:00 ET ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences

 
Jan 30, 07

06:00 ET ZymoGenetics Begins Clinical Trial for PEG-Interferon lambda as Potential Treatment for Viral Infection

 
Jan 04, 07

06:00 ET ZymoGenetics to Highlight Development Programs at JP Morgan Healthcare Conference

 
Dec 20, 06

01:00 ET ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis

 
Dec 18, 06

06:00 ET ZymoGenetics Submits Biologics License Application to the FDA for rhThrombin as an Aid to Controlling Bleeding During Surgery

 
Dec 14, 06

16:10 ET ZymoGenetics Highlights Development Programs at Annual Analyst & Investor Briefing

 
Dec 12, 06

08:30 ET ZymoGenetics Presents Results From Two Atacicept Phase 1b Clinical Trials in B-Cell Cancer

 
Nov 21, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Piper Jaffray Conference

 
Nov 13, 06

01:00 ET ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus

 
Nov 10, 06

06:00 ET ZymoGenetics to Review Development Programs at Credit Suisse Conference

 
Nov 01, 06

16:05 ET ZymoGenetics Reports Third Quarter 2006 Financial Results

 
Oct 25, 06

06:00 ET ZymoGenetics to Host Conference Call and Webcast on November 1, 2006 to Discuss Third Quarter Results

 
Oct 17, 06

06:00 ET ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer

 
Sep 20, 06

17:00 ET ZymoGenetics to Highlight Development Programs at UBS Global Life Sciences Conference

 
Sep 18, 06

06:00 ET ZymoGenetics Discusses Detailed Results From Successful Phase 3 Trial Evaluating rhThrombin as a Potential Treatment for Surgical Bleeding

 
Sep 05, 06

16:10 ET ZymoGenetics Reports Positive Results From Pivotal Phase 3 Clinical Trial of rhThrombin

 
06:00 ET ZymoGenetics to Highlight Development Programs at Upcoming Bear Stearns Healthcare Conference

 
Aug 14, 06

16:05 ET ZymoGenetics Files Lawsuit Against Bristol-Myers Squibb for Infringement of Fusion Protein Patents

 
Aug 03, 06

06:00 ET ZymoGenetics Reports Second Quarter 2006 Financial Results

 
Jul 25, 06

06:00 ET ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus

 
Jul 12, 06

06:00 ET ZymoGenetics Begins Phase 1 Trial With IL-21 and Rituxan(R) in Patients With Non-Hodgkin's Lymphoma

 
Jun 26, 06

01:00 ET ZymoGenetics and Serono Present Positive Results of TACI-Ig Phase 1b Trial in Rheumatoid Arthritis at EULAR Meeting

 
Jun 20, 06

06:00 ET ZymoGenetics Completes Enrollment for rhThrombin Phase 3 Trial

 
Jun 07, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Pacific Growth Equities Investor Conference

 
Jun 05, 06

06:00 ET ZymoGenetics Reports Encouraging IL-21 Phase 1b Results in Metastatic Melanoma and Renal Cell Cancer Presented at ASCO Meeting

 
May 11, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Two Upcoming Investor Conferences

 
May 04, 06

06:00 ET ZymoGenetics Reports First Quarter 2006 Financial Results

 
May 03, 06

06:00 ET ZymoGenetics Names Vaughn Himes Senior Vice President of Technical Operations

 
May 01, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Morgan Stanley Global Healthcare Unplugged Conference

 
Apr 25, 06

06:00 ET ZymoGenetics Names Michael Dwyer Senior Vice President of Marketing and Sales

 
Mar 15, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Invest Northwest Conference

 
Mar 13, 06

06:00 ET Dr. Judith Hemberger Joins ZymoGenetics Board of Directors

 
Mar 02, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Lehman Brothers Investor Conference

 
Feb 15, 06

06:00 ET George B. Rathmann, Ph.D. to Retire from ZymoGenetics Board of Directors

 
Feb 10, 06

06:00 ET ZymoGenetics to Highlight Development Programs at Upcoming BIO CEO & Investor Conference

 
Feb 09, 06

06:00 ET ZymoGenetics Reports Fourth Quarter and Year End 2005 Financial Results

 
Feb 02, 06

06:03 ET ZymoGenetics to Highlight Development Programs at Upcoming Merrill Lynch Investor Conference

 
Jan 10, 06

06:00 ET ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis

 
Jan 05, 06

06:00 ET ZymoGenetics to Highlight Development Programs and Discuss Preliminary Findings from TACI-Ig Phase 1b Clinical Trial in RA at Upcoming Investor Conference

 
Dec 12, 05

13:00 ET ZymoGenetics Announces Presentation of TACI-Ig Phase 1 Preliminary Findings in Multiple Myeloma at American Society of Hematology Meeting

 
Dec 08, 05

13:00 ET ZymoGenetics Highlights Development Programs at Analyst & Investor Briefing

 
Nov 14, 05

06:01 ET ZymoGenetics Presents IL-21 Clinical Study Results at International Society for Biological Therapy of Cancer Conference

 
Nov 03, 05

06:00 ET ZymoGenetics Reports Third Quarter 2005 Financial Results

 
Nov 02, 05

06:00 ET ZymoGenetics to Highlight Development Programs at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2007 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.